ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s KEYTRUDA® (pembrolizumab) for treatment of...
-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the...
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more...
GLENDALE, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- New users often do not know the difference between Delta 8 and...
BURLINGTON, Mass. and JERUSALEM, Aug. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
• TransCon PTH could, if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an...
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an...
Company encouraged by medicinal and therapeutic regulatory developments in Costa Rica Z Strain Psilocybe cubensis Optimi Health, Z Strain Psilocybe...
Lab Reaching Out to Georgia-based School Administrators to Assist with Outbreak PlansNEW YORK, NY and TEL AVIV, Israel, Aug. 26,...
Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment...
Patient denied testing for weeks due to risk of physician infection & non-MSM status Amerimmune Long COVID Panel and Provista...
August 29 webinar will detail the research and success of the clinical trial from the Sagol CenterORLANDO, Fla., Aug. 24,...
Skylight Health Research continues to see success and trial awardsTORONTO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc....
VANCOUVER, British Columbia, Aug. 24, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022...
Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as...
Former Medicine Development Leader for MAGE-A4+ Autologous Cell Therapies Will Support Advancement of CDR-Life’s M-gager® Solid Tumor TherapiesZÜRICH, Switzerland, Aug....
Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in...